Funding News Edition: November 17, 2021 See more articles in this edition
Consider responding to a reissued notice of special interest (NOSI) if somatic cell gene editing (SCGE) and transplantation research fall into your area of scientific focus. Specifically, the NOSI: Somatic Cell Gene Editing Therapies To Improve Transplantation Outcomes* supports multidisciplinary research collaborations that apply SCGE approaches to improve graft survival and outcomes for recipients of allogenic solid organ, pancreatic islet, or vascularized composite allograft (VCA) transplants.
*This Notice replaces and rescinds NOT-AI-21-067.
You may use various models, including human tissues or organs excluded from clinical use and/or rodent, porcine, or nonhuman primate models. Be sure to address unmet needs in VCA, islet, or organ allotransplantation, e.g., preventing or treating rejection; achieving transplant tolerance; and prolonging allograft survival.
NIAID’s areas of research interest include but are not limited to the following:
- Disrupting deleterious genes that contribute to ischemia-reperfusion injury, cellular rejection, or antibody-mediated rejection
- Inserting or amplifying protective genes to prevent drug-related toxicities or promote robust transplant tolerance
- Generating gene-edited cellular therapies to regulate immune responses to the graft, expand the pool of suitable donor organs, or repair recipient organ or tissue damage to partially restore function as a bridge to transplant
Read the NOSI for complete details. You may also refer to our September 15, 2021 Funding News article, but keep in mind it describes the previous NOSI, which was rescinded.
Application and Submission
This NOSI is for due dates on or after February 5, 2022, and subsequent receipt dates through January 7, 2025. Note: Since FORMS-G grant application forms and instructions go into effect for due dates on or after January 25, 2022, you must use the FORMS-G application package. For instructions, go to NIH’s How To Apply—Application Guide.
Apply through the following announcements or their reissued equivalents:
- R01. PA-20-185, NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed). The first due date is February 5, 2022.
- R21. PA-20-195, NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed). The first due date is February 16, 2022.
You must follow all instructions in the SF 424 (R&R) Application Guide and include “NOT-AI-21-080” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF 424 (R&R) form. Applications without this information in box 4B will not be considered for this NOSI.
For applications to NIAID, direct your scientific/research inquiries to Dr. Nasrin Nabavi at firstname.lastname@example.org or 240-627-3538.